Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Berzosertib (VE-822) 已用于研究卵巢肿瘤、卵巢浆液性肿瘤、成人实体瘤、晚期实体瘤和晚期实体瘤等治疗的试验。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 268 | 现货 | ||
2 mg | ¥ 377 | 现货 | ||
5 mg | ¥ 678 | 现货 | ||
10 mg | ¥ 973 | 现货 | ||
25 mg | ¥ 1,860 | 现货 | ||
50 mg | ¥ 3,190 | 现货 | ||
100 mg | ¥ 3,990 | 现货 | ||
200 mg | ¥ 5,810 | 现货 | ||
500 mg | ¥ 8,880 | 现货 | ||
1 g | ¥ 11,900 | 待询 | ||
1 mL * 10 mM (in DMSO) | ¥ 678 | 现货 |
产品描述 | Berzosertib (VE-822) has been used in trials studying the treatment of Ovarian Neoplasms, Ovarian Serous Tumor, Adult Solid Neoplasm, Advanced Solid Tumor, and Advanced Solid Neoplasm, among others. |
靶点活性 | ATR:19 nM |
体外活性 | 和XTR单独作用相比,60 mg/kg VE-822和XTR联用使携带PSN-1和MiaPaCa-2肿瘤的小鼠中肿瘤生长到600 mm3的时间增加一倍.和Gem+XRT1联用相比,60 mg/kg VE-822添加到gemcitabine和XRT的组合中大大延长了PSN-1肿瘤小鼠中肿瘤生长延迟.与XRT1相比,60 mg/kg VE-822和XRT1联用使肿瘤摄取增加44%,这表明VE-822增加了γH2AX磷酸化和XRT引起的DNA损伤持续性.60 mg/kg VE-822抑制小鼠PSN-1肿瘤中丝氨酸345-Chk1的磷酸化. |
体内活性 | 80 nM VE-822单独使用增加MiaPaCa-2和PSN-1细胞停留在G1期的比率。80 nM VE-822消除MiaPaCa-2和PSN-1细胞中富含XRT的G2/M期部分。VE-822单独作用不大,而80 nM VE-822与XRT和/或gemcitabine联用则增强PSN-1细胞中的早期和晚期细胞凋亡。VE-822增加对与pChk1 Ser345阻断相关的DNA损伤剂的肿瘤应答。VE-822(80 nM)减弱ATR信号传导途径并降低肿瘤细胞对XRT和吉西他滨的应答的存活率。在正常细胞中,80 nM VE-822减弱ATR信号通路强度,但并没有增强辐射和gemcitabine杀伤正常细胞的能力。 |
激酶实验 | A375 cells are pre-treated with 1 μM JNK-IN-8 for the indicated amounts of time. Remove the medium and wash 3 times with PBS. Resuspend the cell pellet with 1 mL Lysis Buffer (1% NP-40, 1% CHAPS, 25 mM Tris, 150 mM NaCl, Phosphatase Inhibitor Cocktail, and Protease Inhibitor Cocktail). Rotate end-to-end for 30 min at 4°C. Lysates are cleared by centrifugation at 14000 rpm for 15 min in the Eppendorf. The cleared lysates gel filtered into Kinase Buffer (0.1% NP-40, 20 mM HEPES, 150 mM NaCl, Phosphatase Inhibitor Cocktail, Protease Inhibitor Cocktail) using Bio-Rad 10DG colums. The total protein concentration of the gel-filtered lysate should be around 5-15 mg/mL. Cell lysate is labeled with the probe from ActivX at 5 μM for 1 hour. Samples are reduced with DTT, and cysteines are blocked with iodoacetamide and gel filtered to remove excess reagents and exchange the buffer. Add 1 volume of 2X Binding Buffer (2% Triton-100, 1% NP-40, 2 mM EDTA, 2X PBS) and 50 μL streptavidin bead slurry and rotate end-to-end for 2 hours, centrifuge at 7000 rpm for 2 min. Wash 3 times with 1X Binding Buffer and 3 times with PBS. Add 30 μL 1X sample buffer to beads, heat samples at 95°C for 10 min. Run samples on an SDS-PAGE gel at 110V. After transferred, the membrane is immunoblotted with JNK antibody[1]. |
细胞实验 | VE-822 is dissolved in DMSO and stored, and then diluted with appropriate media before use[1]. Gemcitabine (10 nM) is added 24 h pre-XRT and is replaced with fresh medium before addition of VE-822. PSN-1 cells are treated with VE-822 (80 nM) for 1 h before, through to 18 h after, XRT (6 Gy). Apoptosis is analyzed 48 h after XRT by flow cytometry using an Annexin V-FITC kit with PI[1]. |
别名 | VX-970, VE-822 |
分子量 | 463.55 |
分子式 | C24H25N5O3S |
CAS No. | 1232416-25-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 34 mg/mL (73.3 mM)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.1573 mL | 10.7863 mL | 21.5726 mL | 53.9316 mL |
5 mM | 0.4315 mL | 2.1573 mL | 4.3145 mL | 10.7863 mL | |
10 mM | 0.2157 mL | 1.0786 mL | 2.1573 mL | 5.3932 mL | |
20 mM | 0.1079 mL | 0.5393 mL | 1.0786 mL | 2.6966 mL | |
50 mM | 0.0431 mL | 0.2157 mL | 0.4315 mL | 1.0786 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Berzosertib 1232416-25-9 DNA Damage/DNA Repair PI3K/Akt/mTOR signaling ATM/ATR VE 822 VX 970 VX-970 VX970 VE822 VE-822 Inhibitor inhibitor inhibit